Is MCK or REGN cheaper?

On trailing earnings, REGN is cheaper: MCK trades at a 19.51 P/E and REGN at 14.86.

Which has grown faster, MCK or REGN?

Over the past five years, MCK grew revenue faster — MCK at a 11.11% CAGR versus REGN at 10.16%.

Does MCK or REGN pay a bigger dividend?

MCK yields 0.44% and REGN yields 0.60% based on trailing dividends and the latest price.

Is MCK or REGN more profitable?

REGN runs the higher net margin — MCK at 1.18% versus REGN at 29.65%.

Which has been the better investment, MCK or REGN?

Over the past 10-year, MCK delivered the higher annualized total return — MCK at 16.38% versus REGN at 5.67%. Past performance doesn't predict future results.

McKesson Corporation (MCK) vs Regeneron Pharmaceuticals, Inc. (REGN)

REGN leads on 9 of 15 compared metrics.

A side-by-side comparison of McKesson Corporation and Regeneron Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 19, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).

Regeneron Pharmaceuticals, Inc.

$62.84B

$609.94Healthcare

Total return — MCK vs REGN

growth of $100 · last 30y

MCK +3003.1%REGN +3740.9%REGN compounded faster

MCK REGN

MCK vs REGN: by the numbers

•MCK is the larger company ($87.88B vs $62.84B market cap).
•REGN trades at the lower earnings multiple (14.86 vs 19.51 P/E).
•REGN converts more revenue to profit (29.65% vs 1.18% net margin).
•MCK grew revenue faster over the past five years (11.11% vs 10.16% CAGR).
•REGN pays the higher dividend yield (0.60% vs 0.44%).

Which is better, MCK or REGN?

Metric tally: MCK 6 · REGN 9

It depends on what you're optimizing for:

ValueREGN(lower P/E)

GrowthMCK(faster 5Y revenue CAGR)

IncomeREGN(higher dividend yield)

QualityMCK(higher ROIC)

Metrics side by side

Valuation

Metric	MCK	REGN
P/E ratio	19.51	14.86●
Forward P/E	14.90	11.26●
P/S ratio	0.23●	4.40
P/B ratio	—	2.09
PEG ratio	0.46●	3.38
EV / EBITDA	13.79	11.39●
FCF yield	6.44%	6.33%

Profitability

Metric	MCK	REGN
Gross margin	3.61%	84.55%●
Operating margin	1.58%	24.32%●
Net margin	1.18%	29.65%●
ROE	-219.24%	14.08%●
ROIC	31.48%●	8.51%

Dividends

Metric	MCK	REGN
Dividend yield	0.44%	0.60%●
Payout ratio	8.51%	8.45%

Growth (annualized)

Metric	MCK	REGN
Revenue CAGR (5Y)	11.11%●	10.16%
EPS CAGR (5Y)	40.71%●	5.70%
FCF CAGR (5Y)	8.76%	15.42%●
Total return CAGR (5Y)	33.07%●	2.71%

Frequently asked

Which is better, MCK or REGN?: It depends on your goal. value: REGN (lower P/E); growth: MCK (faster 5Y revenue CAGR); income: REGN (higher dividend yield); quality: MCK (higher ROIC). Across all compared metrics, REGN leads 9 to 6.
Is MCK or REGN cheaper?: On trailing earnings, REGN is cheaper: MCK trades at a 19.51 P/E and REGN at 14.86.
Which has grown faster, MCK or REGN?: Over the past five years, MCK grew revenue faster — MCK at a 11.11% CAGR versus REGN at 10.16%.
Does MCK or REGN pay a bigger dividend?: MCK yields 0.44% and REGN yields 0.60% based on trailing dividends and the latest price.
Is MCK or REGN more profitable?: REGN runs the higher net margin — MCK at 1.18% versus REGN at 29.65%.
Which has been the better investment, MCK or REGN?: Over the past 10-year, MCK delivered the higher annualized total return — MCK at 16.38% versus REGN at 5.67%. Past performance doesn't predict future results.

Go deeper

Full MCK analysis Full REGN analysis Interactive comparison tool

Dig into the metrics

McKesson P/E ratio Regeneron Pharmaceuticals P/E ratio McKesson dividend yield Regeneron Pharmaceuticals dividend yield McKesson ROE Regeneron Pharmaceuticals ROE McKesson operating margin Regeneron Pharmaceuticals operating margin McKesson revenue growth Regeneron Pharmaceuticals revenue growth McKesson free cash flow Regeneron Pharmaceuticals free cash flow

McKesson & Regeneron Pharmaceuticals appear in these rankings

Highest ROIC Stocks Highest FCF Yield Stocks Best 10-Year Total Return Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 19, 2026.